Sign In
Buy RDHL
$1.00
-0.0100 (-0.99%)
At Close: Jun 03, 2026
RedHill's stock is up 7.0% as it shares new data about experimental COVID-19 drug
08:48am, Monday, 04'th Oct 2021
Shares of Redhill Biopharma Ltd. RDHL, -4.59% gained 7.0% in premarket trading on Monday after the company said it had new data from a Phase 2/3 clinical study evaluating its experimental oral antivir
62% statistically significant reduction in mortality shown for moderately severe COVID-19 patients group treated with opaganib vs. the placebo-controlled arm (7 deaths in the 117-patient opaganib arm
RedHill Settles Movantik Patent Litigation With Aurobindo
11:11am, Thursday, 23'rd Sep 2021
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced a settlement and license agreement with Aurobindo Pharma USA Inc resolving their patent litigation in the U.S. The litigation was related to Aur
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo
07:00am, Thursday, 23'rd Sep 2021
TEL AVIV, Israel and RALEIGH, N.C., Sept. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study
12:59pm, Wednesday, 15'th Sep 2021
RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goa
RedHill Biopharma (NASDAQ:RDHL) announced that South Africa has joined the US in approving the Phase 2/3 study of its once-daily, orally administered pill RHB-107 (upamostat) for non-hospitalized pati
Why RedHill Biopharma Stock Is Getting Crushed Today
12:02pm, Tuesday, 14'th Sep 2021
A clinical failure is sending shareholders to the exits this morning.
What's Happening With RedHill Biopharma's Stock On Tuesday?
08:54am, Tuesday, 14'th Sep 2021
RedHill Biopharma Ltd (NASDAQ: RDHL) announced preliminary top-line data from Phase 2/3 study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Read Next: RedHill Biop
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients
08:15am, Tuesday, 14'th Sep 2021
TEL AVIV, Israel and RALEIGH, NC, Sept. 14, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma To Test Its Oral Antiviral In COVID-19 Patients In South Africa
09:10am, Monday, 13'th Sep 2021
Regulatory authorities in South Africa have signed off RedHill Biopharma Ltd's (NASDAQ: RDHL) Phase 2/3 study evaluating RHB-107 (upamostat) for non-hospitalized patients with symptomatic COVID-19.
RHB-107 P2/3 COVID-19 Study South Africa Approval
07:02am, Monday, 13'th Sep 2021
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval The South African Health Products Regulatory Aut
The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not
RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis
11:45am, Wednesday, 08'th Sep 2021
Opaganib, Redhill's (RDHL) candidate for COVID-19, achieves a significant reduction in kidney fibrosis in preclinical studies.
RedHill Biopharma notes study demonstrates opaganib's efficacy in significantly decreasing renal fibrosis
07:02am, Wednesday, 08'th Sep 2021
RedHill Biopharma Ltd. has announced the results of a new preclinical study with its oral pill drug candidate opaganib (ABC294640), demonstrating its efficacy in significantly decreasing renal fibrosi
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
07:02am, Tuesday, 07'th Sep 2021
COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive p
